CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 30 target
Drug / intervention
Zanubrutinibdrug
Likely dose
Zanubrutinib 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05214391
NCT05214391Phase 2RecruitingUpdate OverdueUpdated 16mo ago · Completion was 6mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

Safety and Efficacy of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China·interventional·Posted Jan 28, 2022·Updated Feb 24, 2025

In Brief

A Phase 2 clinical trial evaluating Zanubrutinib for Immune Thrombocytopenia and Treatment. Currently recruiting, targeting 30 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

To evaluate the safety and efficacy of zanubrutinib in the treatment of immune thrombocytopenia in 30 patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune Thrombocytopenia, Treatment
CountriesChina
Collaborators--

Timeline

Phase 2RecruitingOverdue
20222023202420252026
First PostedJan 28, 2022
Enrollment StartFeb 15, 2022
Primary CompletionDec 31, 2025
TodayJul 1, 2026
Enrollment to primary: 3.9 yearsPosted 4.4 years ago

Interventions

Zanubrutinibdrug

The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the investigator will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks. In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate.